DAMORA THERAPEUTICS, INC.

Analyst Reco. Damora Therapeutics, Inc.

Stocks

DMRA

US36322Q2066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/06/2026 BST			5-day change	1st Jan Change
21.36 ^USD	+6.00%		-4.26%	-7.17%

06-11	HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target	MT
06-08	TD Cowen Initiates Damora Therapeutics at Buy	MT

Analyst Reco.

06-11	HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target	MT
06-08	TD Cowen Initiates Damora Therapeutics at Buy	MT
05-28	Wedbush Initiates Damora Therapeutics at Outperform With $35 Price Target	MT
04-24	RBC Initiates Damora Therapeutics at Outperform, Speculative Risk With $40 Price Target	MT
12-01	Guggenheim Initiates Coverage on Galecto With Buy Rating, $32 Price Target	MT
10/06/24	Oppenheimer Adjusts Price Target on Galecto to $9 From $10, Maintains Outperform Rating	MT
28/09/23	HC Wainwright Downgrades Galecto to Neutral From Buy	MT
21/08/23	HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	MT
20/06/23	Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target	MT
17/03/23	Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target	MT
03/08/22	SVB Securities Adjusts Galecto's Price Target to $13 from $16, Keeps Outperform Rating	MT
14/02/22	Credit Suisse Trims Galecto's Price Target to $6 from $7, Maintains Outperform Rating	MT
06/08/21	GALECTO : Credit Suisse Lowers Galecto's PT to $7 from $12 on Lower Projected Sales for GB0139, Reduced Near-Term M&A Expectations; Keeps Outperform Rating	MT
16/03/21	GALECTO : Credit Suisse Lowers Galecto's PT to $12 from $29 After Recommendation to End Parts of GB0139 Phase 2 Study, Keeps Outperform Rating	MT
16/03/21	GALECTO : SVB Leerink Adjusts Galecto's Price Target to $16 From $27, Keeps Outperform Rating	MT
23/11/20	GALECTO : Credit Suisse Initiates Coverage on Galecto With Outperform Rating, $29 Price Target	MT
23/11/20	GALECTO : BofA Securities Initiates Coverage on Galecto With Buy Rating, $21 Price Target	MT
23/11/20	GALECTO : SVB Leerink Starts Galecto at Outperform With $27 Price Target	MT

No results match your criteria

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!